Immune cell therapy using iPS cells

DOI Web Site PubMed
  • YANO Hisashi
    Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University Department of Hematology and Oncology, Graduate School of Medicine, Nagoya University
  • KANEKO Shin
    Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University

Bibliographic Information

Other Title
  • iPS細胞を用いた免疫細胞療法
  • iPS サイボウ オ モチイタ メンエキ サイボウ リョウホウ

Search this article

Abstract

<p>Adoptive cell therapy using tumor-infiltrating T cells has shown durable responses in patients with melanoma, and immunotherapy using genetically engineered T cells (TCR-T or CAR-T) is rapidly emerging as a promising treatment, especially for hematological malignancies. However, the progress is limited because of the lack of readily available good-quality human T cells. Although the efficacy of adoptive cell therapy correlates with the quality of infusing T cells, most antigen-specific T cells in patients with cancer have been exhausted. To overcome this, we have reprogrammed donor (or original) T cells to iPS cells (T-iPS) and differentiated these into rejuvenated antigen-specific cells (T-iPS-T). Moreover, iPS cells provide an unlimited source of genetically engineered T cells such as TCR/CAR-T or PD-1 knockout T cells. The iPS cells’ potential for immune cell therapy is infinite.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 59 (2), 225-231, 2018

    The Japanese Society of Hematology

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top